Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
GY.9NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.7.1 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.254NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.36.1 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.36.12NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.177.21NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.122.2 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AQ.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.1.1.7NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.209NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.236NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.33NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XQNUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.177.59NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.395NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.120.2.1 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.416.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.532NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.408NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XHNUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.290NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.341NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.161NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.69 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.139NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.508NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.94NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.463NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.357NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.318NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.557NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.119NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.160NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
D.4NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.447NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.110.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.180NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.155NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.92NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.145NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.120NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.77NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AE.5NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.504NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AE.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.201NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.221NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.410NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.411NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.310NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used